Three Rivers/Par, Sandoz Ribavirin ANDAs Approved By FDA; Companies Will Share Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
Three Rivers/Par launch Ribasphere at a 10% discount to Schering-Plough’s Rebetol. The generics are approved for use in combination with interferon alfa-2b for the treatment of hepatitis C.
You may also be interested in...
Roche's Copegus Meets Generic Competition
FDA approves ANDAs filed by Three Rivers, Teva and Zydus, with Three Rivers offering a higher-dose tablet than currently available from the brand company.
Roche's Copegus Meets Generic Competition
FDA approves ANDAs filed by Three Rivers, Teva and Zydus, with Three Rivers offering a higher-dose tablet than currently available from the brand company.
Revenues Up Despite Paroxetine Competition And Disappointing Ribavirin Launch, Par Says
Par's second quarter revenues jumped despite disappointing revenues from the company's ribavirin generic and lower sales for paroxetine